Lyra Therapeutics (LYRA) Return on Capital Employed (2020 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Return on Capital Employed of 102.09% in Q4 2025, down 11.77% on a QoQ basis from 91.34% in Q3 2025, and up 5870.0% YoY from 1.71% in Q4 2024.
Lyra Therapeutics (LYRA) Return on Capital Employed (2020 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Return on Capital Employed for 6 consecutive years, with 102.09% the latest figure, recorded in Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 102.09%, up 5870.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 102.09% (up 5870.0% YoY), and the FY2025 annual result was 74.38%, up 3052.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 102.09%, down from 91.34% in the prior quarter.
- The five-year high for Return on Capital Employed was 35.48% in Q1 2021, with the low at 163.79% in Q1 2025.
- A 5-year average of 88.44% and a median of 69.26% in 2021 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 12824 bps in 2022 and jumped 9342 bps in 2023, its largest moves.
- Lyra Therapeutics' Return on Capital Employed stood at 101.27% in 2021, then surged by 45 bps to 56.17% in 2022, then slipped by 7 bps to 59.93% in 2023, then plunged by 168 bps to 160.79% in 2024, then jumped by 37 bps to 102.09% in 2025.
- The last three Return on Capital Employed figures came in at 102.09% (Q4 2025), 91.34% (Q3 2025), and 95.92% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -102.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -102.09% |
| Sep 30, 2025 | -91.34% |
| Jun 30, 2025 | -95.92% |
| Mar 31, 2025 | -163.79% |
| Dec 31, 2024 | -160.79% |
| Sep 30, 2024 | -141.42% |
| Jun 30, 2024 | -107.11% |
| Mar 31, 2024 | -59.45% |
| Dec 31, 2023 | -59.93% |
| Sep 30, 2023 | -63.33% |
| Jun 30, 2023 | -66.69% |
| Mar 31, 2023 | -70.30% |
| Dec 31, 2022 | -56.17% |
| Sep 30, 2022 | -49.30% |
| Jun 30, 2022 | -65.37% |
| Mar 31, 2022 | -163.72% |
| Dec 31, 2021 | -101.27% |
| Sep 30, 2021 | -68.23% |
| Jun 30, 2021 | -47.02% |
| Mar 31, 2021 | -35.48% |